EDIT
Editas Medicine, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.16
+2.60%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−4.1x
Market Cap
$485.31M
MomentumView details →
1D Return
+2.60%
YTD Return
+51.36%
RSI (14)
53.5
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−4.1x
Market Cap
$485.31M
RSI (14)
53.5
MomentumView details →
1D Return
+2.60%
YTD Return
+51.36%
SummaryUpdated Jun 1, 2026
Editas Medicine, Inc. (NASDAQ:EDIT) is a clinical-stage biotechnology company founded in 2013 and based in Cambridge, Massachusetts. The company was originally incorporated as Gengine, Inc. before changing its name in November 2013. Editas went public in February 2016 and has since established itself as a pioneer in the genome editing field, focusing on developing transformative genomic medicines using CRISPR technology to treat serious diseases. The company operates primarily in the gene therapy and cell therapy sectors, with programs targeting inherited diseases, blood disorders, and cancer.
Similar companies
Latest newsMore news →
Editas Medicine announced that EDIT-401 is on track for CTN submission this month, with data update expected in Q1 2027.30d agoEditas Medicine announced a recent financing that strengthens its capital position, extending cash runway into the second half of 2028.30d agoEditas Medicine reported financial results for the second quarter of 2026 and provided business updates.30d ago